Wells Fargo’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.67M Buy
151,040
+118,278
+361% +$1.83M ﹤0.01% 3403
2025
Q4
$667K Buy
32,762
+6,872
+27% +$121K ﹤0.01% 4262
2025
Q3
$410K Buy
25,890
+3,945
+18% +$58.3K ﹤0.01% 4449
2025
Q2
$293K Buy
21,945
+5,167
+31% +$69.8K ﹤0.01% 4515
2025
Q1
$171K Buy
16,778
+1,570
+10% +$18.2K ﹤0.01% 4809
2024
Q4
$241K Buy
15,208
+4,153
+38% +$216K ﹤0.01% 4679
2024
Q3
$642K Sell
11,055
-464
-4% -$22.9K ﹤0.01% 3836
2024
Q2
$526K Buy
11,519
+2,210
+24% +$119K ﹤0.01% 3883
2024
Q1
$616K Buy
9,309
+3,363
+57% +$199K ﹤0.01% 3754
2023
Q4
$236K Sell
5,946
-9,292
-61% -$291K ﹤0.01% 4370
2023
Q3
$486K Sell
15,238
-6,085
-29% -$227K ﹤0.01% 3802
2023
Q2
$857K Buy
21,323
+7,016
+49% +$308K ﹤0.01% 3574
2023
Q1
$611K Buy
14,307
+14,260
+30,340% +$720K ﹤0.01% 3707
2022
Q4
$2.26K Sell
47
-618
-93% -$28.9K ﹤0.01% 5986
2022
Q3
$25K Sell
665
-3,512
-84% -$122K ﹤0.01% 5289
2022
Q2
$115K Buy
4,177
+2,694
+182% +$118K ﹤0.01% 4564
2022
Q1
$81K Sell
1,483
-5,351
-78% -$275K ﹤0.01% 5422
2021
Q4
$400K Buy
6,834
+6,831
+227,700% +$341K ﹤0.01% 4838
2021
Q3
$0 Sell
3
-6
-67% -$214 ﹤0.01% 7292
2021
Q2
$0 Sell
9
-422
-98% -$22.9K ﹤0.01% 7212
2021
Q1
$27K Sell
431
-19,083
-98% -$1.21M ﹤0.01% 6065
2020
Q4
$1.38M Buy
19,514
+6,992
+56% +$441K ﹤0.01% 3782
2020
Q3
$483K Buy
12,522
+499
+4% +$19.8K ﹤0.01% 4367
2020
Q2
$451K Buy
+12,023
New +$370K ﹤0.01% 4404

Other funds holding KROS